MRg-NIRS Imaging System Breast Cancer Trial
Part of paid clinical trials in Lebanon, New Hampshire.
- Sponsor
- Keith D. Paulsen
- Study ID
- NCT06400563
- Status
- Recruiting
Conditions
Eligibility Criteria
- Sex
- FEMALE
- Age
- 18 Years - 83 Years
- Healthy Volunteers
- Not accepted
Interventions
- MRg-NIRS — DEVICEThe trial tests the investigator designed and developed Magnetic Resonance-guided (MRg) Near-infrared Spectroscopy (NIRS) imaging system for breast cancer detection. The wearable NIRS imaging system uses 8 flex circuit strips, each with six photo-detectors (PDs) and six source fibers, that are ready to attach to a breast radially by using an adhesive nipple cover and breast tape.
Study Details
This trial is a study of 20 women with breast cancer to evaluate the addition of MR-guided (MRg) near-infrared spectroscopy (NIRS) with and without contrast, as part of a program to improve clinical management of women receiving breast magnetic resonance imaging (MRI).
Key Dates
- Start date
- Sep 23, 2024
- Status verified
- Nov 2025
- Primary completion
- Dec 31, 2026
- Completion
- Mar 31, 2027
Study Design
- Enrollment
- 20 participants (estimated)
- Allocation
- NA
- Intervention model
- SINGLE_GROUP
- Primary purpose
- DEVICE_FEASIBILITY
Arms
- Other: MR-guided NIRSThe MRg-NIRS device will be tested to see if it accommodates different breast sizes, covers the breast fully, includes the axilla, is compatible with commercial breast MRI coil and/or biopsy systems, and the signal-to-noise ratio is high enough for MRg-NIRS image reconstruction. The study team will collect MRI-derived ROI data with T1, T2 and DCE-MRI sequences from 20 women with breast abnormalities and NIRS data concurrently. The study team will also collect diffuse optical signals at 48x48 detector source positions over one side of breast at 6 wavelengths.
Primary Outcome Measure
Optical sensitivity of the MRg-NIRS platform [ Time Frame: up to one hour on day of MRI ]
Central Contacts
- Keith D. Paulsen, PhD603-646-2695
- Shudong Jiang, PhD
Locations (1)
| Facility | City | State | ZIP | Site coordinators |
|---|---|---|---|---|
| Dartmouth-Hitchcock Medical Center | Lebanon | New Hampshire | 03756 | Keith D Paulsen, PhD Roberta diFlorio-Alexander, MD (SUB_INVESTIGATOR) Shudong Jiang, PhD (SUB_INVESTIGATOR) Keith D Paulsen, PhD (PRINCIPAL_INVESTIGATOR) |
Find similar trials in Lebanon, NH
By condition
By specialty
By research site
Related Studies
- Regional Radiotherapy in Biomarker Low-Risk Node Positive and T3N0 Breast CancerPHASE3 · Recruiting · Canadian Cancer Trials Group · Fairbanks, Alaska
- ATEMPT 2.0: Adjuvant T-DM1 vs THPHASE2 · Recruiting · Dana-Farber Cancer Institute · San Francisco, California
- Evaluating the Addition of Adjuvant Chemotherapy to Ovarian Function Suppression Plus Endocrine Therapy in Premenopausal Patients With pN0-1, ER-Positive/HER2-Negative Breast Cancer and an Oncotype Recurrence Score Less Than or Equal to 25PHASE3 · Recruiting · NRG Oncology · Birmingham, Alabama
- Cognitive Training for Cancer Related Cognitive Impairment in Breast Cancer SurvivorsRecruiting · NRG Oncology · Anchorage, Alaska